

## FW: FOI 24/018 - Freedom of Information Request

FOILicensing <FOILicensing@mhra.gov.uk>

Fri 02/02/2024 17:18

To: MHRA Customer Services <MHRACustomerServices@mhra.gov.uk>

Cc: [REDACTED] FOILicensing  
<FOILicensing@mhra.gov.uk>

Hi [REDACTED]

Thanks for your help, this one has now been sent out.

Kind regards

---

**From:** FOILicensing <FOILicensing@mhra.gov.uk>

**Sent:** Friday, February 2, 2024 5:16 PM

**To:** [REDACTED]

**Subject:** FOI 24/018 - Freedom of Information Request

**Importance:** High

### FOI 24/018

Dear [REDACTED]

Many thanks for your email dated 07 January 2024, where you asked for the following information:

*Please provide a list of all medicinal products whose licensing authorisations (Temporary use, conditional use and marketing authorisations) were signed by Lord Bethel during his tenure (2020 - 2021) as Parliamentary Under Secretary of State (Minister for Technology, Innovation and Life Sciences) and the dates for those authorisations.*

### Our response

Please note that the grant letters for Marketing Authorisations are signed by MHRA on behalf of the Secretary of State for Health.

Submissions for the following Regulation 174 product decisions were sent to Lord Bethell for approval, as follows:

- Pfizer COVID-19 vaccine– submission sent 30 November 2020, approval decision published 02 December 2020, authorised 01 December 2020.
- AstraZeneca COVID-19 vaccine– submission sent on 29 December 2020, approval decision published 30 December 2020, authorised 30 December 2020.
- Moderna COVID-19 vaccine– submission sent on 06 January 2021, approval decision published 08 January 2021, authorised 08 January 2021.
- Sanofi Flublok vaccine- submission sent on 06 October 2020, approval decision published 22 October 2020, authorised 21 October 2020.

Regulation 174 is the mechanism which allows for temporary authorisation of an unlicensed medicine, such as a vaccine, where such an authorisation is needed in response to certain public health threats, such as a pandemic. These authorisations do not constitute a marketing authorisation.

We now consider this response closed. If you disagree with how we have interpreted the Freedom of Information Act 2000 in answering your request, you can ask us to review our

actions and decisions by writing to: [info@mhra.gov.uk](mailto:info@mhra.gov.uk), and requesting an internal review.

Please note that your internal review request must be in a recordable format (email, letter, audio tape etc.), and that you have 40 working days upon receipt of this letter to ask for a review. We aim to provide a full response to your review request within 20 working days of its receipt. Please quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you would have the right to apply directly to the Information Commissioner for a decision. Please bear in mind that the Information Commissioner will not normally review our handling of your request unless you have first contacted us to conduct an internal review. The Information Commissioner can be contacted online via an electronic form: <https://ico.org.uk/make-a-complaint/foi-and-eir-complaints/foi-and-eir-complaints/>

or in writing to:

Information Commissioner's Office,  
Wycliffe House,  
Water Lane,  
Wilmslow,  
Cheshire,  
SK9 5AF

Yours sincerely,

HQA FOI Team

---

**From:** [REDACTED]  
**Sent:** Sunday, January 7, 2024 11:55 AM  
**To:** MHRA Customer Services <[MHRACustomerServices@mhra.gov.uk](mailto:MHRACustomerServices@mhra.gov.uk)>  
**Subject:** FOI 24/018 - Freedom of Information Request

You don't often get email from [REDACTED]

To whom it may concern,

Please provide a list of all medicinal products whose licensing authorisations (Temporary use, conditional use and marketing authorisations) were signed by Lord Bethel during his tenure (2020 - 2021) as Parliamentary Under Secretary of State (Minister for Technology, Innovation and Life Sciences) and the dates for those authorisations.

Yours sincerely,

[REDACTED]

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is

prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)

DISCLAIMER This email and any files transmitted with it are confidential. If you are not the intended recipient, any reading, printing, storage, disclosure, copying or any other action taken in respect of this email is prohibited and may be unlawful. If you are not the intended recipient, please notify the sender immediately by using the reply function and then permanently delete what you have received. Incoming and outgoing email messages are routinely monitored for compliance with the Department of Health's policy on the use of electronic communications. For more information on the Department of Health's email policy, click [DHTermsAndConditions](#)